29 August 2012
Angel Biotechnology Holdings plc
("Angel" or "the Company")
Angel andarGentis Pharmaceuticals LLCsign Framework Agreement
Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, is pleased to announce the signing of a framework agreement with arGentis Pharmaceuticals LLC ("arGentis") which establishes the parameters of future contracts for the development and manufacture of their collagen product, ARG201, a treatment for the life-threatening autoimmune disease, systemic sclerosis.
Dr Stewart White, ABH Commercial Director and Acting CEO said: "We are very pleased to be able to assist arGentis by providing material for this serious clinical indication. This demonstrates not only the commercial demand for the collagen products that Angel can offer, but the value Angel can offer customers towards accelerating clinical supply."
Mr Tom Davis, President of arGentis Pharmaceuticals, LLC said: "Angel offers a unique combination of product and service that has been a real challenge for our business to identify. We look forward to a long and fruitful relationship with Angel and an expeditious entry of our product to the clinic."
For further information:
Angel Biotechnology Holdings plc
Lorna Peers, Finance Director +44 (0) 131 445 6077
Stewart White, Acting CEO/Commercial Director www.angelbio.com
Grant Thornton, Corporate Finance
Colin Aaronson / Melanie Frean +44 (0) 20 7383 5100
Hybridan LLP (Broker)
Claire Noyce, Deepak Reddy +44 (0) 20 7947 4350
Media enquiries:
The Communications Portfolio Ltd
distributed by |